Insomnia Insights and Interventions in Alzheimer’s Disease
Activity Description
Nearly half of Alzheimer’s patients cannot sleep at night compared with healthy adults in the same age group. This causes nighttime wandering and worsens cognition and depression, and creates a significant burden for patients and caregivers. Sleeplessness is thought to contribute to the accumulation of amyloid and tau; sleep disturbance and disease progression in Alzheimer’s disease are correlated. Providers who care for individuals with Alzheimer’s disease need to stay current about the science of the sleep/wake cycle in their patients and need to be aware of current and emerging treatments that affect patients’ lives and their caregivers’ lives.
Target Audience
This activity is intended for health care professionals engaged in the care of patients with Alzheimer’s disease.
Educational Objectives
After completing this activity, the participant should be better able to:
- Discuss the burden of insomnia in individuals with Alzheimer’s disease
- Analyze the role of the orexin signaling system in the sleep/wake cycle and changes that occur in individuals with Alzheimer’s disease
- Evaluate the efficacy and safety data from recent clinical trials of orexin inhibitors in individuals with mild-to-moderate Alzheimer’s disease and implications for clinical practice
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
| Faculty | Relationship Identified With: |
|---|---|
| David A. Smith, MD, CMD | Consulting fees from Acadia and Urovant Sciences |
| Brendan P. Lucey, MD, MSCI | Dr Lucey has nothing to disclose. |
Planners and Managers
The PIM planners and managers have nothing to disclose. The Miller Medical Communications, LLC, planners and managers have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Miller Medical Communications, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider Information
Jointly provided by Postgraduate Institute for Medicine and Miller Medical Communications, LLC
Financial Support
This activity is supported by an independent educational grant from Merck & Co., Inc.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation and Request for Credit
In order to claim credit, participants must complete the following:
- There are no fees for participating in and receiving CME/CE credit for this activity.
- During the period December 20, 2019, through December 20, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
- If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation.
- Upon registering and successfully completing the post-test and with 3 out of 4 correct or better and the activity evaluation, your certificate will be made available immediately.
Contact Information for Questions About the Activity
System Requirements
Performedia requires a modern web browser (Microsoft Edge, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software.
Release date: December 20, 2019
Expiration date: December 20, 2020
Estimated time to completion: 1.0 hours